Maze SVP exercises options, sells 2,500 shares
Maze Therapeutics SVP of Finance Amy Bachrodt exercised stock options and sold shares in a planned transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics SVP of Finance Amy Bachrodt exercised stock options and sold shares in a planned transaction. She exercised options to acquire 2,500 shares of Common Stock at $10.42 per share, then sold a total of 2,500 shares in open-market trades at weighted average prices of $29.3227 and $30.3367 per share. These sales were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025. Following the transactions, she directly owns 12,965 shares of Common Stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,500 shares ($48K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Bachrodt Amy
Role
SVP, Finance
Sold
2,500 shs ($74K)
Approx. gross sale proceeds
$74K
Approx. exercise cost
$26K
Approx. pre-tax spread
$48K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,500 | $10.42 | $26K |
| Sale | Common Stock | 2,200 | $29.3227 | $65K |
| Sale | Common Stock | 300 | $30.3367 | $9K |
Holdings After Transaction:
Stock Option (Right to Buy) — 33,833 contracts (Direct);
Common Stock — 12,965 shares (Direct)
Footnotes (4)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.85 to $29.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $30.50 per share, inclusive.
- F4. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Options Exercised: 2,500 shares
Exercise Price: $10.42 per share
Shares Sold (first block): 2,200 shares
+4 more
7 metrics
Options Exercised
2,500 shares
Stock options exercised into Common Stock on 2026-04-01 at $10.42
Exercise Price
$10.42 per share
Conversion price for 2,500 options into Common Stock
Shares Sold (first block)
2,200 shares
Common Stock sold at weighted average $29.3227 on 2026-04-01
Shares Sold (second block)
300 shares
Common Stock sold at weighted average $30.3367 on 2026-04-01
Post-transaction holdings
12,965 shares
Common Stock directly owned after reported sales
Net share change
-2,500 shares
Net of 2,500 options exercised and 2,500 shares sold
Net-sell direction
2,500 shares
transactionSummary shows net-sell of Common Stock
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average price, Exercise or conversion of derivative security, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)"
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security"
open-market sale financial
"transaction_action": "open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"The option vested or vests as to 1/48th of the total award monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Maze Therapeutics (MAZE) SVP Amy Bachrodt do in this Form 4 filing?
Amy Bachrodt exercised stock options and sold shares. She acquired 2,500 Maze Therapeutics common shares via option exercise, then sold 2,500 shares in open-market transactions, all under a pre-arranged Rule 10b5-1 trading plan.
What option exercise is reported in this Maze Therapeutics (MAZE) Form 4?
The Form 4 reports Amy Bachrodt exercising options for 2,500 Maze Therapeutics common shares at an exercise price of $10.42 per share, converting a derivative position into directly held stock before executing related open-market sales.
Were the Maze Therapeutics (MAZE) insider sales made under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Amy Bachrodt on September 29, 2025, indicating the trades were pre-scheduled rather than discretionary market-timing decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
